Bristol Myers Squibb

News

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

A pair of trials have suggested that CAR-T therapies could offer an improved option for patients with large B cell lymphoma (LBCL) who have relapsed after or haven't responded to first-line

News

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

The FDA has kicked off its review of Bristol-Myers Squibb's psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU and Japanese regulators also start

News

BMS strikes back against Merck in EU oesophageal cancer mark...

Merck & Co's Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment in the EU earlier this year, but will now face competition from B

Sales & Marketing

BMS’ Catherine Owen: Hybrid communication is here to stay

The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation.

News

Scotland backs Cabometyx combo for kidney cancer, amid stall...

Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb's immunotherapy Opdivo with Ipsen's targeted drug Cabometyx, ahead o

News

Failed IBD trial dents confidence in BMS' deucravacitinib

Bristol-Myers Squibb's hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure in ulce

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

FDA sets Sept review date for BMS' psoriasis drug deucravaci...

BMS strikes back against Merck in EU oesophageal cancer mark...

BMS’ Catherine Owen: Hybrid communication is here to stay

Scotland backs Cabometyx combo for kidney cancer, amid stall...

Failed IBD trial dents confidence in BMS' deucravacitinib

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks